Sen. Gregg Eyes Flu Vaccine Manufacturer Liability Protections In Biodefense Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
The Senate Appropriations/Homeland Security Subcommittee chairman indicates he may consider stronger liability protections for flu vaccine manufacturers in S 3, his biodefense bill.
You may also be interested in...
HHS In Final Phases Of Acquiring Additional Countermeasures Under BioShield
Department is nearing contract completion for anthrax therapeutics, botulinum antitoxin and a next-generation smallpox vaccine. HHS has awarded three contracts since passage of BioShield legislation, for recombinant protective antigen anthrax vaccine, potassium iodide and anthrax vaccine adsorbed.
HHS In Final Phases Of Acquiring Additional Countermeasures Under BioShield
Department is nearing contract completion for anthrax therapeutics, botulinum antitoxin and a next-generation smallpox vaccine. HHS has awarded three contracts since passage of BioShield legislation, for recombinant protective antigen anthrax vaccine, potassium iodide and anthrax vaccine adsorbed.
Population-Wide Smallpox Vaccination Urged At Senate Hearing
Smallpox vaccination should be reinstated for the entire U.S. population, MIT’s Deutch suggests. Additional research on other biological threats is called for; federal funding is recommended instead of relying on industry initiative, due to lack of market incentives.